Prognosis of younger patients in non-small cell lung cancer

Slides:

Advertisements

Similar presentations

LUNG CANCER LUNG CANCER Lung Cancer  What Is Lung Cancer?  Lung Cancer is a disease caused by the rapid growth and division of cells that make up the.

Advertisements

Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice.

North Tees University Hospital Audit of T1 Rectal Cancers September 2013 – August 2014 Nicola Maguire Teaching fellow General Surgery 12/09/2014.

62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.

Giving Induction Radiation in Addition to Chemotherapy Is Not Associated with Improved Survival of NSCLC Patients with Operable Mediastinal Nodal Disease.

Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine.

Clinical features and outcome in ovarian sarcomas: Analysis of a single-institution experience A López Pousa, X Gonzàlez Farré, MJ. Quintana, S Bagué,

Pneumonectomy for Locally Advanced Lung Cancer after Neoadjuvant Concurrent Chemo-radiation Therapy K. Okabe, H. Tao, T. Tanaka, T. Hayashi, K. Yoshiyama,

Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. Eng C1, Rogers J2, Chang GJ3, You N3, Das P4, Rodriguez-Bigas.

Skull Base Chordoma and Chondrosarcoma: Changes in National Radiotherapy Patterns and Survival Outcomes Henry S. Park, MD, MPH; Kenneth B. Roberts, MD;

Multimodality therapy for locally advanced thymomas: a cohort study of prognostic factors from a European multicentric database Dr. GIOVANNI LEUZZI Department.

LUNG ADENOCARCINOMAS. CLINICOPATHOLOGICAL STUDY WITH RESPECT TO THE UPCOMING NEW CLASSIFICATION AND EGFR-KRAS MUTATION ANALYSIS IMPLICATIONS. First author:

Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.

SEER Provided Data Mohammad Afnan Baqai 12/3/2009.

The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.

on behalf of the ACOSOG Z4032 Investigators

The Royal Marsden Solitary fibrous tumours The outcomes of 106 patients illustrating the unpredictable biological behaviour N Alexander, K Thway, JM Thomas,

Clinicopathologic Features of EML4-ALK Mutant Lung Cancer Shaw AT et al. ASCO 2009; Abstract (Poster)

Erlotinib Therapy in Non Small Cell Lung Cancer Patients - Survival of Patients on Reduced Erlotinib Doses M. Pesek 1, J. Krejci 1, J. Skrickova 2, P.

Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.

Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer in the Elderly: A Population-Based Study in Ontario, Canada JOURNAL OF CLINICAL ONCOLOGY, VOLUME 30.

Lung cancer Gene Kukuy, MD Cardiothoracic Surgery.

Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,

Lung Cancer in Never-Smokers from the Princess Margaret Cancer Centre 1 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;

Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients.

Brain imaging prior to lung cancer resection

Papillary Thyroid Cancer Treated at the Mayo Clinic, 1946 Through 1970: Initial Manifestations, Pathologic Findings, Therapy, and Outcome WILLIAM M.

Prognostic significance of tumor subtypes in male breast cancer:

R. Michelle Sarin, MD Mentor: Jeffrey Fowler, MD

Lung squamous cell carcinoma

Securing the cure in resectable lung cancer

Fig. 3 Overall and disease-free survival of single-zone metastasis group according to the number of stations involved. No significant differences were.

Fig 1A. Patient enrollment flow chart

A Hussain, S Qadri, Y Haqzad, M Chaudhry, A Cale, M Cowen, M Loubani.

Compassionate People World Class Care

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

New perioperative risk factors for biochemical recurrence after robotic assisted radical prostatectomy: A single surgeon experience in high volume Canadian.

Concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after chemoradiation: outcome and survival S.T. Heijkoop1,2; H.C. van.

PUBLISH ONLY Journal of Thoracic Oncology

Intervista a Lucio Crinò

Department of Surgery, Taipei Veterans General Hospital Huang Kuo-Hung

Improved survival outcomes after resection of ductal adenocarcinoma in the body and tail of the pancreas: A single center 10 years’ experience Seong.

The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

EVALUATE EFFECTIVENESS OF GEFIITINIB IN FIRST LINE TREATIMENT AVANCED NSCLC PATIENTS WITH EGFR MUTATION BS TRẦN THỊ CHUNG, Ths. NGUYỄN THỊ OANH Oncology.

Significance of P53 and Rb protein expression in surgically treated non-small cell lung cancers Yung-Chie Lee, MD, PhD, Yih-Leong Chang, MD, Shi-Ping.

Case 1: Introduction. Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?

MJ O’Connell for the ACCENT Collaborative Group

Telomere Length and Recurrence Risk after Curative Resection in Patients with Early- Stage Non–Small-Cell Lung Cancer: A Prospective Cohort Study Eric.

Conditional Cancer-Specific Versus Cardiovascular-Specific Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer Shawn S. Groth, MD, MS, Natasha.

Clinicopathologic Features of Resected Subcentimeter Lung Cancer

PUBLISH ONLY Journal of Thoracic Oncology

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,

THE PROGNOSIS OF COLORECTAL CANCER IN YOUNGER PATIENTS Mohamed Zied Ben Abdessalem, Amine Gouader, Mohamed Salah Jarrar, Fatma medhioub, Mohamed Hedi.

Results of surgical intervention for p-stage IIIA (N2) non–small cell lung cancer: Acceptable prognosis predicted by complete resection in patients with.

Valerie W Rusch, MD, Ennapadam S Venkatraman, PhD

Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis Alessandro Marra, MD, PhD, Ludger Hillejan, MD,

Supplementary Table S2 Correlation between pre-operative plasma miR-451 or miR-486 concentrations and clinicopathologic features in gastric cancer patients.

James D Luketich, Michael E Burt The Annals of Thoracic Surgery

Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer Steven M Keller, MD, Sudeshna Adak,

Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer Bernward Passlick, MD, Boris Kubuschok, MD,

Trends in survival from metastatic lung cancer in California,

Figure S1. A. B. Figure S1. Kaplan-Meier curve of progression-free survival by treatment group in soluble heregulin (HRG)-high population (A) and soluble.

Prognosis of angiosarcoma at different anatomic sites

The SUV on 18F-FDG-PET/CT imaging as an independent predictor for overall survival and disease free survival after hepatectomy of Hepatocellular carcinoma（

Prognostic effect of complete pathologic response following TACE on HCC patients undergoing liver resection or transplantation Prognostic effect of complete.

Surgical resection of metachronous liver metastases

Results: Purpose/Objectives: Methods: Conclusions:

Machine learning analysis for predicting survival in stage III non-small cell lung cancer patients receiving definitive chemotherapy and proton radiation.

Presentation transcript:

Prognosis of younger patients in non-small cell lung cancer

Purpose This study is to compare clinicopathological characteristics, treatment modalities, and prognosis of non-small cell lung cancer (NSCLC) patients between <50 years and >50 years of age at surgery.

Methods Retrospective review of 2,618 patients with NSCLC who underwent curative intent surgical resection from 2003 to 2015 was obtained from prospectively collected lung cancer database. There were 274 patients (10%) of <50 years old at time of surgery and 2,344 of >50 years. Data regarding demographics, presenting symptoms, histology, tumor staging, treatment modalities (neo, surgical extent, adjuvant therapy), and recurrence, survival were evaluated.

Results Overall survival Time at risk Death Incident rate n (%) (95%CI) median time (month) Log-rank test Death 669(2.66) 28.27-33.17 30.37 0.001 Age < 50 45(2.51) 23.97-43.70 34.57 Age > 50 624(2.67) 27.93-33.10 30.30

Overall survival in each stage Stage 1 n=1,474 P <0.001 Stage 2 n=464 P=0.098 Stage3 n=437 P=0.121 Log rank test  Age <50  Age >50 Stage 4 n=114 P=0.855

Conclusion The younger patients (<50 years of age at surgery) were more female, never smoker, and adenocarcinoma. Even though there was no difference in treatment modalities, younger patients had significantly better prognosis in pathologic stage I NSCLC.